Company Showcase Musculoskeletal system and connective tissue

WuXi AppTec&AZ

WuXi AppTec&AZ is a joint venture between AstraZeneca’s subsidiary MedImmune and Shanghai WuXi AppTec. Its main product WBP216 is a recombinant human anti-interleukin-6 monoclonal antibody for the treatment of rheumatoid arthritis. The mechanism of the product is clear, the production process is stable, the administration is convenient, and it can treat diseases caused by IL-6 / IL-6R signaling pathway.